Fig 1.
Rapid DNA Vaccine Manufacturing in Response to Influenza Pandemic.
Fig 2.
Number of individuals assessed for eligibility, enrolled and followed up.
Table 1.
Baseline Characteristics of Participants.
Table 2.
Frequency of Adverse Events.
Fig 3.
(A) Hemagglutination Inhibition (HAI) assay with A/Mexico/4482/2009 H1N1 virus (B) Neutralizing antibodies were evaluated by the capacity of sera to prevent infection of 293A cells by replication-incompetent H1-pseudotyped virus. The 80% inhibition serum titers are shown. (C) End-point ELISA titers of H1 A/California/04/2009(H1N1) specific antibodies are shown. Pre-vaccination titers have been subtracted from each plotted value. (D) H1-specific T cell responses are shown as a number of spot forming cells (SFC) per 106 PBMC as measured by ELISpot assay. Geometric means and 95% CI are shown for the study groups.